San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Fate Therapeutics is raising $50,000,024.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Scott Wolchko played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. Our first-in-class cell therapy product candidates undergoing clinical development today utilize healthy donor cells, which we modify ex vivo using pharmacologic modulators, such as small molecules, to improve the cells’ biological properties and therapeutic function. We are also pioneering a revolutionary approach to cell therapy we use renewable master induced pluripotent stem cell (iPSC) lines generated from our proprietary iPSC platform to derive cell therapy product candidates that can be delivered off-the-shelf for the treatment of a large number of patients.

To learn more about Fate Therapeutics, visit http://fatetherapeutics.com/

Contact:
Scott Wolchko, President and Chief Executive Officer
858-875-1803
scott.wolchko@fatetherapeutics.com
https://www.linkedin.com/in/scott-wolchko-3720906/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved